Class Action Alerts for PayPal and REGENXBIO Investors
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy PYPL?
Source: Globenewswire
- PayPal Lawsuit Overview: The class action against PayPal alleges that during the period from February 25, 2025, to February 2, 2026, management misrepresented the company's revenue outlook, resulting in a stock price drop of over 20% following disappointing earnings announced on February 3, 2026.
- CEO Transition Impact: The lawsuit highlights that after the release of underwhelming financial results, PayPal announced the transition of CEO James Alexander Chriss, exacerbating market concerns about the company's future and undermining investor confidence.
- REGENXBIO Lawsuit Context: The class action involving REGENXBIO pertains to its gene therapy product RGX-111, with allegations that management disseminated false information from February 9, 2022, to January 27, 2026, leading to a 17.8% stock price decline after the FDA imposed a clinical hold on its trials.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 due to the discovery of a brain tumor in a trial participant, raising serious concerns among investors regarding the product's safety and efficacy, which negatively impacted the company's market performance.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PYPL?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PYPL
Wall Street analysts forecast PYPL stock price to rise
29 Analyst Rating
6 Buy
19 Hold
4 Sell
Hold
Current: 44.630
Low
51.00
Averages
72.86
High
100.00
Current: 44.630
Low
51.00
Averages
72.86
High
100.00
About PYPL
PayPal Holdings, Inc. offers a technology platform. The Company’s products are designed to enable digital payments and simplify commerce experiences for consumers and merchants to make selling, shopping, and sending and receiving money simple, personalized, and secure, online or offline, including mobile. It provides consumers with a digital wallet that enables them to send payments to merchants securely using a variety of funding sources, which include a bank account, a PayPal or Venmo account balance, its consumer credit products, a credit card, a debit card, certain cryptocurrencies, or other stored value products. It operates a global, two-sided network at scale that connects consumers and merchants with 434 million active accounts across approximately 200 markets. Its brands include PayPal, Braintree, Venmo, Xoom, Hyperwallet, PayPal Zettle, PayPal Honey, and Paidy. It offers financing products through the PayPal Working Capital (PPWC) and PayPal Business Loan (PPBL).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Class Action Alerts for PayPal and REGENXBIO Investors
- PayPal Lawsuit Overview: The class action against PayPal alleges that during the period from February 25, 2025, to February 2, 2026, management misrepresented the company's revenue outlook, resulting in a stock price drop of over 20% following disappointing earnings announced on February 3, 2026.
- CEO Transition Impact: The lawsuit highlights that after the release of underwhelming financial results, PayPal announced the transition of CEO James Alexander Chriss, exacerbating market concerns about the company's future and undermining investor confidence.
- REGENXBIO Lawsuit Context: The class action involving REGENXBIO pertains to its gene therapy product RGX-111, with allegations that management disseminated false information from February 9, 2022, to January 27, 2026, leading to a 17.8% stock price decline after the FDA imposed a clinical hold on its trials.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 due to the discovery of a brain tumor in a trial participant, raising serious concerns among investors regarding the product's safety and efficacy, which negatively impacted the company's market performance.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: During the period from February 2024 to February 2026, PayPal is accused of overstating its business execution capabilities, leading to investor misconceptions about the company's prospects, which is expected to negatively impact its stock price.
- NuScale Power Risk Disclosure: NuScale is charged with failing to disclose significant risks related to its commercialization strategy during the period from May to November 2025, which could undermine investor confidence in its nuclear projects and affect future financing capabilities.
- Corcept Therapeutics Regulatory Issues: From October 2024 to December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, which may lead to significant obstacles in future drug approvals, impacting company operations.
- Navan IPO Controversy: During its IPO in 2025, Navan is charged with failing to disclose a 39% increase in sales and marketing expenses, which could mislead investors about its financial health and affect its market performance.
See More
PayPal Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against PayPal for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 25, 2025, and February 2, 2026, with a deadline to contact the firm by April 20, 2026.
- False Statements Allegation: The complaint alleges that PayPal made false and misleading statements regarding its Branded Checkout business growth potential, despite knowing its salesforce was incapable of achieving the claimed growth, which misled investors during the class period.
- Investor Losses: Following the revelation of the truth about PayPal's capabilities, investors suffered damages, indicating that the company's public statements were materially misleading, which could lead to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them for a free discussion of their rights before the class action is certified, ensuring that investors can effectively protect their interests.
See More
Coinbase Receives Conditional Approval to Operate as a Trust Bank
- Trust Bank Approval: Coinbase has received conditional approval from the U.S. Office of the Comptroller of the Currency (OCC) to operate as a trust bank, which will enable it to expand payment products under federal supervision, enhancing its competitive edge in the crypto payments sector.
- Regulatory Advantage: By being directly regulated by the OCC rather than state-level authorities, Coinbase will simplify its operations and reduce compliance costs, allowing the company to operate more effectively in the fast-evolving crypto industry.
- Payment Strategy Development: Coinbase has established a payment strategy centered around the stablecoin USDC, launching the Coinbase Payments product and collaborating with Shopify to position USDC as a mainstream global payment method, thereby increasing its market share.
- Clear Market Goals: CEO Brian Armstrong has set an ambitious goal to make USDC the number one stablecoin globally and aims to position Coinbase as the leading financial services app in the coming years, reflecting its aspirations in the crypto finance landscape.
See More
PayPal Class Action Notice and Deadline
- Class Action Notice: Rosen Law Firm reminds investors who purchased PayPal stock between February 25, 2025, and February 2, 2026, to apply as lead plaintiffs by April 20, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that PayPal misled investors by providing overly optimistic information regarding its 2027 financial targets while concealing the salesforce's inability to effectively capitalize on growth potential, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
PayPal Faces Class Action Lawsuit Over Leadership Change and Financial Targets
- Lawsuit Background: Hagens Berman has filed a securities class action lawsuit against PayPal and its executives due to a surprise leadership change and the abrupt withdrawal of long-term financial targets, severely undermining investor confidence.
- Lawsuit Details: The lawsuit, filed in the U.S. District Court for the Northern District of California, alleges that PayPal violated federal securities laws during the Class Period from February 25, 2025, to February 2, 2026, seeking to recover losses for all investors who purchased PayPal common stock during this timeframe.
- Investor Action: Investors are urged to apply by April 20, 2026, to become Lead Plaintiff in the lawsuit, highlighting a strong concern for corporate governance and transparency among shareholders.
- Internal Disclosure Issues: The allegations of
See More
Class Action Alerts for PayPal and REGENXBIO Investors
- PayPal Lawsuit Overview: The class action against PayPal alleges that during the period from February 25, 2025, to February 2, 2026, management misrepresented the company's revenue outlook, resulting in a stock price drop of over 20% following disappointing earnings announced on February 3, 2026.
- CEO Transition Impact: The lawsuit highlights that after the release of underwhelming financial results, PayPal announced the transition of CEO James Alexander Chriss, exacerbating market concerns about the company's future and undermining investor confidence.
- REGENXBIO Lawsuit Context: The class action involving REGENXBIO pertains to its gene therapy product RGX-111, with allegations that management disseminated false information from February 9, 2022, to January 27, 2026, leading to a 17.8% stock price decline after the FDA imposed a clinical hold on its trials.
- Clinical Trial Issues: On January 28, 2026, REGENXBIO announced that the FDA placed a clinical hold on RGX-111 due to the discovery of a brain tumor in a trial participant, raising serious concerns among investors regarding the product's safety and efficacy, which negatively impacted the company's market performance.
See More
Multiple Companies Face Class Action Lawsuits
- PayPal Lawsuit Overview: During the period from February 2024 to February 2026, PayPal is accused of overstating its business execution capabilities, leading to investor misconceptions about the company's prospects, which is expected to negatively impact its stock price.
- NuScale Power Risk Disclosure: NuScale is charged with failing to disclose significant risks related to its commercialization strategy during the period from May to November 2025, which could undermine investor confidence in its nuclear projects and affect future financing capabilities.
- Corcept Therapeutics Regulatory Issues: From October 2024 to December 2025, Corcept is accused of not disclosing FDA concerns regarding the effectiveness assessment of its drug, which may lead to significant obstacles in future drug approvals, impacting company operations.
- Navan IPO Controversy: During its IPO in 2025, Navan is charged with failing to disclose a 39% increase in sales and marketing expenses, which could mislead investors about its financial health and affect its market performance.
See More
PayPal Faces Class Action Lawsuit Reminder
- Class Action Reminder: The Schall Law Firm reminds investors of a class action lawsuit against PayPal for violations of §§10(b) and 20(a) of the Securities Exchange Act, concerning securities purchased between February 25, 2025, and February 2, 2026, with a deadline to contact the firm by April 20, 2026.
- False Statements Allegation: The complaint alleges that PayPal made false and misleading statements regarding its Branded Checkout business growth potential, despite knowing its salesforce was incapable of achieving the claimed growth, which misled investors during the class period.
- Investor Losses: Following the revelation of the truth about PayPal's capabilities, investors suffered damages, indicating that the company's public statements were materially misleading, which could lead to a decline in investor confidence.
- Legal Consultation Opportunity: The Schall Law Firm encourages affected shareholders to contact them for a free discussion of their rights before the class action is certified, ensuring that investors can effectively protect their interests.
See More
Coinbase Receives Conditional Approval to Operate as a Trust Bank
- Trust Bank Approval: Coinbase has received conditional approval from the U.S. Office of the Comptroller of the Currency (OCC) to operate as a trust bank, which will enable it to expand payment products under federal supervision, enhancing its competitive edge in the crypto payments sector.
- Regulatory Advantage: By being directly regulated by the OCC rather than state-level authorities, Coinbase will simplify its operations and reduce compliance costs, allowing the company to operate more effectively in the fast-evolving crypto industry.
- Payment Strategy Development: Coinbase has established a payment strategy centered around the stablecoin USDC, launching the Coinbase Payments product and collaborating with Shopify to position USDC as a mainstream global payment method, thereby increasing its market share.
- Clear Market Goals: CEO Brian Armstrong has set an ambitious goal to make USDC the number one stablecoin globally and aims to position Coinbase as the leading financial services app in the coming years, reflecting its aspirations in the crypto finance landscape.
See More
PayPal Class Action Notice and Deadline
- Class Action Notice: Rosen Law Firm reminds investors who purchased PayPal stock between February 25, 2025, and February 2, 2026, to apply as lead plaintiffs by April 20, 2026, to participate in the class action and potentially receive compensation.
- Fee Arrangement: Investors joining the class action will incur no out-of-pocket expenses, as the law firm operates on a contingency fee basis, which alleviates financial burdens and encourages broader participation.
- Lawsuit Background: The lawsuit alleges that PayPal misled investors by providing overly optimistic information regarding its 2027 financial targets while concealing the salesforce's inability to effectively capitalize on growth potential, resulting in investor losses when the truth emerged.
- Law Firm's Strength: Rosen Law Firm is renowned for its successful track record in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
See More
PayPal Faces Class Action Lawsuit Over Leadership Change and Financial Targets
- Lawsuit Background: Hagens Berman has filed a securities class action lawsuit against PayPal and its executives due to a surprise leadership change and the abrupt withdrawal of long-term financial targets, severely undermining investor confidence.
- Lawsuit Details: The lawsuit, filed in the U.S. District Court for the Northern District of California, alleges that PayPal violated federal securities laws during the Class Period from February 25, 2025, to February 2, 2026, seeking to recover losses for all investors who purchased PayPal common stock during this timeframe.
- Investor Action: Investors are urged to apply by April 20, 2026, to become Lead Plaintiff in the lawsuit, highlighting a strong concern for corporate governance and transparency among shareholders.
- Internal Disclosure Issues: The allegations of
See More
